Abstract
With the recognition in the early 1960s that histones can be post-translationally modified, the list of different post-translational modifications of histones and their biological consequences has continued to expand. In addition, the idea of the ‘histone code’ hypothesis, later introduced by David Allis and colleagues, further broaden the horizon of chromatin biology. Currently, there is a wealth of knowledge about the transition between the active and the repressive state of chromatin, and modifications of histones remains at the center of chromatin biology. Histone deacetylases (HDACs) in particular are of great importance for the therapeutic success of cancer treatment. Focusing primarily on HDAC6, herein we have briefly highlighted its unique involvement in cancer and also apparently in neurodegeneration.
Plain language summary
Cancer (uncontrolled cell proliferation) and neurodegenerative diseases (loss of neurons/protein aggregation) are two distinct pathological conditions that share/overlap certain molecular determinants. Histone deacetylase 6 appears to be one such determinant for which researchers have made significant progress by accumulating sufficient evidence for its clinical translation in these aforementioned disease conditions.
Tweetable abstract
Be it cancer or neurodegeneration, understanding the dynamics of histone modifications continues to be of great interest, and histone deacetylase 6 (HDAC6) now apparently is at the forefront.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA 51(5), 786–794 (1964).
- 2. . Translating the histone code. Science 293(5532), 1074–1080 (2001).
- 3. . Epigenetic regulatory enzymes: mutation prevalence and coexistence in cancers. Cancer Invest. 39(3), 257–273 (2021).
- 4. . Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 280(3), 775–793 (2013). • Discusses why HDAC6 is unique compared with other histone deacetylase family members.
- 5. Curriculum vitae of HDAC6 in solid tumors. Int. J. Biol. Macromol. 230, 123219 (2023).
- 6. Histone deacetylase 6 in cancer. J. Hematol. Oncol. 11(1), 111 (2018).
- 7. . HDAC6 in diseases of cognition and of neurons. Cells 10(1), (2020). •• A paper on the role of HDAC6 in various signaling pathways associated with early and advanced cancers and neurological diseases.
- 8. . A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019). Expert Opin. Ther. Pat. 30(2), 121–136 (2020).
- 9. . HDAC6 as privileged target in drug discovery: a perspective. Pharmacol. Res. 163, 105274 (2021).
- 10. . Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment. BMC Med. Genomics 16(1), 295 (2023).
- 11. . The role of HDAC6 in cancer. J. Biomed. Biotechnol. 2011, 875824 (2011).
- 12. . Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53(3), 267–277 (2008).
- 13. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 7(12), 1403–1412 (2012).
- 14. Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma. Onco. Targets Ther. 10, 5129–5136 (2017).
- 15. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer. Hum. Pathol. 75, 16–25 (2018).
- 16. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24(28), 4531–4539 (2005).
- 17. . HDAC6 and ovarian cancer. Int. J. Mol. Sci. 14(5), 9514–9535 (2013).
- 18. Up-regulation of HDAC6 results in poor prognosis and chemoresistance in patients with advanced ovarian high-grade serous carcinoma. Anticancer Res. 41(3), 1647–1654 (2021).
- 19. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Sci. Rep. 9(1), 2397 (2019).
- 20. Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma. Int. J. Exp. Pathol. 96(4), 248–254 (2015).
- 21. . Citarinostat and momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Apoptosis 25(5–6), 370–387 (2020).
- 22. . Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother. Pharmacol. 83(2), 255–264 (2019).
- 23. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol. Oncol. 10(5), 735–750 (2016).
- 24. . HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener. 8, 7 (2013).
- 25. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat. Commun. 11(1), 5522 (2020).
- 26. . HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma. Sci. Rep. 12(1), 10513 (2022).
- 27. . HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cancer Biomark. 19(2), 169–175 (2017).
- 28. . Upregulated histone deacetylase 6 associates with malignant progression of melanoma and predicts the prognosis of patients. Cancer Manag. Res. 12, 12993–13001 (2020).
- 29. Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer. Cancer Manag. Res. 10, 5451–5460 (2018).
- 30. . Targeting STAT3 in cancer immunotherapy. Mol. Cancer 19(1), 145 (2020).
- 31. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics 11(14), 7029–7044 (2021).
- 32. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J. Exp. Clin. Cancer Res. 38(1), 149 (2019).
- 33. CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res. 77(18), 5118–5128 (2017).
- 34. Preclinical platforms to study therapeutic efficacy of human gammadelta T cells. Clin. Transl. Med. 12(6), e814 (2022).
- 35. . CIK cells and HDAC inhibitors in multiple myeloma. Int. J. Mol. Sci. 18(5), (2017).
- 36. . 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J. Exp. Clin. Cancer Res. 40(1), 388 (2021).
- 37. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis. 11(6), 417 (2020).
- 38. Efficacy of cytokine-induced killer cell immunotherapy for patients with pathologically pure glioblastoma. Front. Oncol. 12, 851628 (2022).
- 39. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget 8(4), 7003–7013 (2017).
- 40. . Marginalizing the genomic architecture to identify crosstalk across cancer and neurodegeneration. Front. Mol. Neurosci. 16, 1155177 (2023). •• Discusses the involvement of certain common genes or shared pathways in cancers and neurodegenerative diseases.
- 41. Ubiquitin carboxyl-terminal hydrolases (UCHs): potential mediators for cancer and neurodegeneration. Int. J. Mol. Sci. 21(11), (2020). •• Discusses the potential mediators for cancer and neurodegeneration.
- 42. . Histone deacetylases as targets for the treatment of neurodegenerative disorders: challenges and future opportunities. Med. Res. Rev. 40(6), 2177–2211 (2020).
- 43. . Histone deacetylase 6 and the disease mechanisms of alpha-synucleinopathies. Front. Synaptic. Neurosci. 12, 586453 (2020).
- 44. . The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6), 727–738 (2003). • First study to report that HDAC6 had high expression in α-synuclein- and ubiquitin-positive Lewy bodies in brain sections of patients with Parkinson's disease.
- 45. . The class II histone deacetylases as therapeutic targets for Parkinson's disease. Neuronal Signal. 4(2), NS20200001 (2020).
- 46. . Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 106(5), 2119–2130 (2008).
- 47. Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. Biochem. Biophys. Res. Commun. 430(1), 394–399 (2013).
- 48. . Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. PLOS ONE 10(5), e0126592 (2015).
- 49. A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington's disease. BMB Rep. 56(2), 178–183 (2023).
- 50. . Hsp90 and its co-chaperones in neurodegenerative diseases. Int. J. Mol. Sci. 20(20), (2019).
- 51. . HSP70 and HSP90 in neurodegenerative diseases. Neurosci. Lett. 716, 134678 (2020).
- 52. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int. J. Cancer 145(3), 735–747 (2019).
- 53. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11(509), (2019).
- 54. . Ricolinostat is not a highly selective HDAC6 inhibitor. Nat. Cancer 4(6), 807–808 (2023).